← All countries · Americas
86.5%
MCV1
2025 · Administrative (country-reported)
89.6%
DTP3
2025 · Administrative (country-reported)
89.6%
IPV complete
2025 · Administrative (country-reported)
83.3%
HepB3
2025 · Administrative (country-reported)
0
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 86.5%2025 · Administrative (country-reported) | 86.5% | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 98.7%2025 · Administrative (country-reported) | 98.7% | D · poor | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 89.6%2025 · Administrative (country-reported) | 89.6% | D · poor | |
| IPV1First dose of inactivated polio vaccine | 98.7%2025 · Administrative (country-reported) | 98.7% | D · poor | |
| IPV completeInactivated polio vaccine, complete primary series | 89.6%2025 · Administrative (country-reported) | 89.6% | D · poor | |
| MCV1First dose of measles-containing vaccine | 86.5%2025 · Administrative (country-reported) | 86.5% | D · poor | |
| MCV2Second dose of measles-containing vaccine | 80.7%2025 · Administrative (country-reported) | 80.7% | D · poor | |
| RCV1First dose of rubella-containing vaccine | 86.5%2025 · Administrative (country-reported) | 86.5% | D · poor | |
| HepB3Third dose of hepatitis B vaccine | 83.3%2025 · Administrative (country-reported) | 83.3% | D · poor | |
| HepB birthHepatitis B birth dose within 24 hours | 71.7%2025 · Administrative (country-reported) | 71.7% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 89.6%2025 · Administrative (country-reported) | 89.6% | D · poor | |
| PCV1Pneumococcal conjugate vaccine, first dose | 95.2%2025 · Administrative (country-reported) | 95.2% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 90.8%2025 · Administrative (country-reported) | 90.8% | D · poor | |
| RotaCRotavirus vaccine, complete series | 82.6%2025 · Administrative (country-reported) | 82.6% | D · poor | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 18.2%2024 · Administrative (country-reported) | 18.2% | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Pertussis (whooping cough) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | C · weak | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02018 | 0per 1,000,000 total population | too few points | D · poor |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (67 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | W6 | General/routine | |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 3 | M6 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 4 | M15 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y4-Y6 | General/routine | Age 4 - 6 years |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | 1st contact | Travellers | International travelers (including students going to college) |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 2 | +M6-M12 | Travellers | International travelers (including students going to college) |
| HEPA_HEPBHepatitis A, Hepatitis B (HepA-HepB) vaccine | 1 | 1st contact | Travellers | Unimmunized international travelers |
| HEPA_HEPBHepatitis A, Hepatitis B (HepA-HepB) vaccine | 2 | +M1 | Travellers | Unimmunized international travelers |
| HEPA_HEPBHepatitis A, Hepatitis B (HepA-HepB) vaccine | 3 | +M6-M12 | Travellers | Unimmunized international travelers |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | >=M12 | Risk group(s) | Unimmunized children from countries with Hepatitis A on schedule or international travelers >=12M |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | >=M12 | Travellers | Unimmunized children from countries with Hepatitis A on schedule or international travelers >=12M |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | +M6-M18 | Risk group(s) | Unimmunized children from countries with Hepatitis A on schedule or international travelers >=12M |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | +M6-M18 | Travellers | Unimmunized children from countries with Hepatitis A on schedule or international travelers >=12M |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | at risk adults, healthcare workers and unimmunized persons |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Risk group(s) | at risk adults, healthcare workers and unimmunized persons |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +W4 | Health workers | at risk adults, healthcare workers and unimmunized persons |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +W4 | Risk group(s) | at risk adults, healthcare workers and unimmunized persons |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | at risk adults, healthcare workers and unimmunized persons |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Risk group(s) | at risk adults, healthcare workers and unimmunized persons |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | birth dose administered at birth to 72 hours |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | W6 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | M9 | General/routine | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y11-Y12 | HPV administered to females and males | Males & Females |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y60 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-Y8 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | 1st contact | Travellers | International travelers as booster dose |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | 1st contact | Risk group(s) | Given only to students going abroad to study or at risk individuals e.g. persons with Sickle Cell Anaemia |
| MEN_BMeningococcal B vaccine | 1 | 1st contact | Risk group(s) | At risk children and adults and travelers |
| MEN_BMeningococcal B vaccine | 1 | 1st contact | Travellers | At risk children and adults and travelers |
| MEN_BMeningococcal B vaccine | 2 | +M2 | Risk group(s) | At risk children and adults and travelers |
| MEN_BMeningococcal B vaccine | 2 | +M2 | Travellers | At risk children and adults and travelers |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M15 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M6 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 4 | M12 | General/routine | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Risk group(s) | Single dose for unimmunized adults (65 yrs and older ). & single dose for Immunocompromised individuals who did not receive the Pneumococcal vaccine. | |
| RABIESRabies vaccine | 1 | 1st contact | Risk group(s) | Vet students, travelers and other risk groups |
| RABIESRabies vaccine | 1 | 1st contact | Travellers | Vet students, travelers and other risk groups |
| RABIESRabies vaccine | 2 | +D7 | Risk group(s) | Vet students, travelers and other risk groups |
| RABIESRabies vaccine | 2 | +D7 | Travellers | Vet students, travelers and other risk groups |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | General/routine | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Pregnant women W27-W36/40 gestation, unique dose each pregnancy | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y14-Y16 | General/routine | Age 14 - 16 yrs |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Adults | Upon first contact, +6W, +6M for unimmunization persons 7 years and older. Adults as booster | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Risk group(s) | Upon first contact, +6W, +6M for unimmunization persons 7 years and older. Adults as booster |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +W6 | Risk group(s) | Upon first contact, +6W, +6M for unimmunization persons 7 years and older. Adults as booster |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Risk group(s) | Upon first contact, +6W, +6M for unimmunization persons 7 years and older. Adults as booster |
| VARICELLAVaricella vaccine | 1 | M12 | General/routine | |
| VARICELLAVaricella vaccine | 2 | Y3-Y4 | General/routine | 2nd dose is at Y3 or Y4 |
| YFYF (Yellow fever) vaccine | 1 | 1st contact | Travellers | unimmunized international travelers single dose |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | >=Y60 | Adults | Adults age 60 and older and other risk adults |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | 1st contact | Risk group(s) | Adults age 60 and older and other risk adults |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M2-M6 | Adults | Adults age 60 and older and other risk adults |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M2-M6 | Risk group(s) | Adults age 60 and older and other risk adults |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.